Corrections & amendments

Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John M. Kirkwood ⓘ , Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller ⓘ , Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy ⓘ , Paolo A. Ascierto ⓘ , Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman & Georgina V. Long ⓘ

In the version of the article initially published, John M. Kirkwood was presented in the author list without a middle initial. The error has been corrected in the HTML and PDF versions of the article.

Publisher Correction: Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary

Intae Moon ⓘ , Jaclyn LoPiccolo, Sylvan C. Baca, Lynette M. Sholl ⓘ , Kenneth L. Kehl ⓘ , Michael J. Hassett, David Liu ⓘ , Deborah Schrag & Alexander Gusev ⓘ

In the version of the article initially published, in Table 1, five cancer types were mistakenly placed under incorrect groups. Invasive breast carcinoma (BRCA), Colorectal adenocarcinoma (COADREAD), Prostate adenocarcinoma (PRAD), Melanoma (MEL) and Gastrointestinal stromal tumor (GIST) now stand as individual cancer groups. In the fifth paragraph of the introduction, the fifth sentence has been updated to read "We applied this classifier, named OncoNPC, to 971 tumor samples from patients with CUP with clinical follow-up at Dana-Farber Cancer Institute (DFCI)." Additionally, Supplementary Data 3 and 5 were interchanged. These changes have been made in the HTML and PDF versions of the article.